GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development
- 1 January 2001
- journal article
- review article
- Published by Portico in Drugs of the Future
- Vol. 26 (7) , 0677-685
- https://doi.org/10.1358/dof.2001.026.07.628723
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily AdministrationJournal of Medicinal Chemistry, 2000
- Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogsDiabetes, 1997
- Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigsDiabetologia, 1996
- Albumin Binding and Time Action of Acylated Insulins in Various SpeciesJournal of Pharmaceutical Sciences, 1996
- Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivoBiochemical Journal, 1995
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992
- GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humansDigestive Diseases and Sciences, 1989
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANPublished by Elsevier ,1987